249 related articles for article (PubMed ID: 26506090)
1. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
2. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
4. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
5. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
6. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.
Lashford LS; Lewis IJ; Fielding SL; Flower MA; Meller S; Kemshead JT; Ackery D
J Clin Oncol; 1992 Dec; 10(12):1889-96. PubMed ID: 1453204
[TBL] [Abstract][Full Text] [Related]
8. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
Howard JP; Maris JM; Kersun LS; Huberty JP; Cheng SC; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2005 Mar; 44(3):232-9. PubMed ID: 15490487
[TBL] [Abstract][Full Text] [Related]
9. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
10. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
[TBL] [Abstract][Full Text] [Related]
11. High-dose
Kayano D; Wakabayashi H; Nakajima K; Kuroda R; Watanabe S; Inaki A; Toratani A; Akatani N; Yamase T; Kunita Y; Hiromasa T; Takata A; Mori H; Saito S; Araki R; Taki J; Kinuya S
Ann Nucl Med; 2020 Jun; 34(6):397-406. PubMed ID: 32219730
[TBL] [Abstract][Full Text] [Related]
12. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
[TBL] [Abstract][Full Text] [Related]
13. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for
Seo Y; Huh Y; Huang SY; Hernandez-Pampaloni JM; Hawkins RA; Gustafson WC; Vo KT; Matthay KK
Med Phys; 2019 May; 46(5):2477-2486. PubMed ID: 30761545
[TBL] [Abstract][Full Text] [Related]
14. Reaching the target dose with one single
Fiz F; Cirone A; Righi S; Massollo M; Amoroso L; Bottoni G; Conte M; Gambaro M; Massone F; Orengo S; Bruzzone GS; Sorrentino S; Garaventa A; Piccardo A
Pediatr Blood Cancer; 2024 Mar; 71(3):e30806. PubMed ID: 38082548
[TBL] [Abstract][Full Text] [Related]
15. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
16. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.
Fielding SL; Flower MA; Ackery D; Kemshead JT; Lashford LS; Lewis I
Eur J Nucl Med; 1991; 18(5):308-16. PubMed ID: 1936038
[TBL] [Abstract][Full Text] [Related]
19. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
DuBois SG; Matthay KK
Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
